Clinical Trial Update: Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing [Phase 4]

View source ↗

Summary

Phase 4 trial updates the recurrence rate of wet age-related macular degeneration in patients stabilized on three-month dosing with ranibizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Age Related Macular Degeneration | Phase 4 | Status: COMPLETED